Introduction
Gene transfer into hematopoietic stem cells has proven to be of therapeutic benefit for the treatment of inherited diseases affecting the immune system. In several phase I clinical trials, functional reconstitution of cellular and innate immunity has been achieved after reinfusion of gene-modified autologous stem cells into the patients. [1] [2] [3] [4] [5] Despite these encouraging results, the occurrence of a lymphoproliferative disease in five patients treated for X-linked severe combined immunodeficiency has questioned the safety of this approach and has motivated intensive activities toward the understanding of vector-cell interactions. [6] [7] [8] [9] [10] [11] [12] Until now, in all gene therapy trials aiming for the correction of immunodeficiencies, retroviral vectors derived from the murine leukemia virus (MLV) were used. In these vectors, the therapeutic gene is under the transcriptional control of the viral long terminal repeat, which normally contains strong enhancer activity. As untargeted integration into the host chromosome is a mandatory step in the retrovirus life cycle, these types of vector are per se mutagenic. Indeed, the retroviral-mediated transcriptional activation of LMO2, a transcription factor essential for T-cell development, was one of the key events associated with the development of lymphoproliferative disease in the X-linked severe combined immunodeficiency trial. 12, 13 In 2004, we initiated a gene therapy trial for the treatment of the X-linked form of chronic granulomatous disease (X-CGD), a severe life-threatening immunodeficiency affecting the capacity of phagocytic neutrophils to generate reactive oxygen species, which are essential for microbicidal activity.
14-17 X-CGD patients are unable to eradicate infections caused by catalase-positive bacteria and fungi. 18 Two young adults were treated with gene-modified autologous CD34+ cells resulting in the eradication of therapy refractory infections. However, an increase in gene-marked granulocytes was observed 5 months after transplantation, which was caused by retroviral-mediated transcriptional activation of MDS1/ EVI1, PRDM16 and SETBP1, genes involved in myeloid cell growth and differentiation. 5 Although cell proliferation may have enhanced the therapeutic effect seen in our trial, the activation by retroviral insertional mutagenesis of well-known proto-oncogenes linked to the development of hematological abnormalities raised significant safety concerns. 19 Despite these events, our trial demonstrated that gene therapy can provide significant clinical benefit to CGD patients and emphasizes the need for a new generation of viral vectors with reduced genotoxicity.
The use of self-inactivating (SIN) vectors harboring deletions in the U3 enhancer/promoter region in combination with internal weaker cellular promoters may provide a safer alternative and create a therapeutic window for the treatment of CGD. However, these vectors have been associated with poor titers and low expression levels. In this study, we present a series of optimization steps leading to the generation of safety improved SIN vectors with high titers and enhanced transgene expression.
Results

Optimization of gp91
phox cDNA sequence results in increased viral titers Retroviral vectors containing an optimized backbone architecture including deletion of enhancer and TATA box (SIN configuration) 20 were cloned for the expression of gp91 phox in hematopoietic cells ( Figure 1 ). Initial attempts to generate high-titer SIN gammaretroviral vector expressing the wild-type version of gp91 phox failed because the titers of the virus produced by transient transfection protocols were low (o5 Â 10 5 TU/ml; Figure 2a ), in contrast to the high titers achieved with similar vectors expressing enhanced green fluorescent protein (eGFP). 20 The inclusion of elements known to enhance titer and transgene expression such as WPRE did not increase titer (data not shown). Therefore, we considered optimization of the gp91 phox cDNA for which a complete new gp91 phox cDNA was synthesized. In addition to codon optimization, the GC content was increased from originally 47% (wild-type gp91 phox cDNA) to 61%. Also putative polyA sites, internal consensus and cryptic splice donor sites and RNA instability motifs were removed (Supplementary Figure  S1) . The optimized gp91 phox cDNA (gp91s) was used to replace the native gp91 phox cDNA in the SIN gammaretroviral vector SERS11.SF.gp91.W to generate SERS11.SF.gp91s.W (Figure 1a) . Inclusion of gp91s into the gamma SIN backbone led to a 10-fold increase in vector titer (Figure 2a) , suggesting increased amounts of packagable viral genomic RNA. Indeed, 293T cells transfected with SERS11.SF.gp91s.W contained 4-6 times more genomic viral RNA than cells transfected with SERS11.SF.gp91.W (Figure 2b ).
Higher reconstitution of superoxide production in X-CGD cells expressing gp91s
The myelomonocytic cell line X-CGD PLB-985 21 SIN vectors for the correction of X-CGD B Moreno-Carranza et al production, NADPH oxidase activity was assessed in transduced and immunomagnetically selected cells after dimethylsulfoxide induced granulocytic differentiation by the cytochrome C assay. 22 Superoxide production in cells transduced with SERS11.SF.gp91s.W was twofold increased as compared with cells transduced with similar vectors expressing native gp91 phox (Figure 3c ). This difference may underestimate the performance of the SERS11.SF.gp91s.W vector as immunomagnetic selection enriches for cells expressing high levels of gp91 phox and thus narrows the differences in the performance of the two vectors.
In further studies, we replaced the strong internal SFFV promoter by the short intronless version of the elongation factor 1 alpha promoter 20, 23, 24 to test whether the gp91s expression levels driven by a weak internal promoter will also result in significant superoxide production levels. X-CGD PLB-985 cells were transduced at low MOI with SERS11.EFs.gp91s.W and cells expressing the transgene were isolated by immunomagnetic sorting. Copy number estimation revealed 1.3 proviral copies per transduced cell. After dimethylsulfoxide induced granulocytic differentiation, the SERS11.EFs.gp91s.W vector was as powerful in superoxide production as the SERS11.SF.gp91s.W vector (Figure 3c ), indicating that high reconstitution of NADPH oxidase activity is possible from a weaker internal promoter if the optimized gp91 phox sequence is used.
SIN lentiviral vectors containing the native or the synthetic gp91 phox were also generated. These vectors were used to transduce lin À bone marrow cells from X-CGD mice at an MOI of 10 and gp91 phox expression was evaluated by FACS 3-4 days after transduction. As observed previously for the SIN gammaretroviral vectors, the inclusion of the synthetic gp91 phox cDNA in these vectors resulted in higher expression efficiency as reflected by the increase in median fluorescence intensity and in the numbers of cells expressing detectable levels of gp91 phox (Figure 3d ). Equal vector copy numbers were observed by real-time PCR in both populations arguing for a better performance of the gp91s expressing lentiviral vector. Similar to the results observed in cell lines, gp91 phox RNA levels were increased by 1.6-fold in cells expressing the synthetic version of gp91 phox (Figure 3e ).
Introduction of gp91s in bicistronic vectors strongly increases transgene expression of the second cistron
In further work, we generated bicistronic SIN lentiviral and SIN gammaretroviral vectors encoding gp91 phox in the first cistron and a fusion of eGFP and the P144K mutant of canine O Although we did not achieve higher transgene expression with the intron containing vector in transduced K562 cells, transgene expression increased 1.6-to 2-fold after introduction of the optimized gp91s cDNA (Figure 4b ). However, in other cell lines and most importantly in human primary CD34+ peripheral blood progenitor cells (PBPCs), incorporation of the MLV-based intron dramatically enhanced transgene expression of gp91 phox and eGFP-DMGMT in comparison to the unmodified lentiviral vector (Figures  4b-d) . The introduction of the synthetic gp91 phox resulted in an even stronger increase in transgene expression also in the absence of the intron, showing that optimization of the first cistron has also a profound effect on expression from the non-optimized second cistron (Figures 4b-d) . The combination of the optimized gp91 phox with the MLV intron in the lentiviral vector L.SF.I.gp91s.iGM.W did not increase transgene expression levels any further (Figures 4b and d) .
As seen with the monocistronic vectors, vector titers were increased for bicistronic vectors containing an optimized gp91 phox about threefold (data not shown). Although transgene expression levels were lower in the non-optimized gammaretroviral vector when compared with the non-optimized lentiviral vector, they were similar in the gp91 phox optimized versions (Figure 4b ). Quantitative PCR in CD34+ PBPC and K562 cells revealed almost equal vector copy numbers per transgene-positive cell for the vectors used (Figure 4c) , confirming that the observed effects were not due to different copy numbers.
Discussion
Insertional oncogenesis caused by retroviral integration is a major concern in gene therapy. Most of the actual vectors in gene therapy trials are long terminal repeatdriven vectors and were derived from MLV because of their well-known biological properties, their innate property to integrate into the genome of the host cells, the simplicity of vector construction and the robust titers achieved in stable packaging systems. However, intensive studies on retroviral integration have revealed that integration of gammaretroviruses is not a random process but occurs semi-randomly with an exquisite preference for promoter-proximal regions in gene-dense regions of the genome. [25] [26] [27] [28] From both promoterproximal and distal positions, transcriptional activation of cellular genes has been observed in a series of in vitro and in vivo approaches, including human gene therapy trials leading to clonal imbalance and eventually malignant transformation. 11, 12, [29] [30] [31] [32] Although insertional mutagenesis cannot be avoided at present, the effects of retrovirus integration on cellular gene expression and physiology can be significantly lowered by modifications within the retroviral backbone. Among others the inclusion of insulators in the viral backbone has been shown to drastically reduce the effects of the viral enhancer on cellular gene expression. 33, 34 Similarly, SIN vectors, in which the viral enhancers are deleted, are significantly less mutagenic than their long terminal repeat-driven counterparts. [35] [36] [37] Depending on the cargo, SIN vectors for the correction of X-CGD B Moreno-Carranza et al however, the SIN configuration often results in lower titers and lower transgene expression. Indeed, our efforts to generate SIN gammaretroviral and lentiviral vectors for clinical application failed at the beginning because titers and transgene expression were below the therapeutic threshold required for a clinical intervention. We reasoned that the cDNA for gp91 phox could be one of the causes of this problem as similar vectors with other transgenes did not show such a drastic reduction in titer and transgene expression. 20 The synthesis of a new gp91 phox cDNA resulted in a significant increase in vector titers and gene expression levels. In our case, this improvement seems to be mainly due to improved mRNA stability and/or transport, as higher gp91 phox mRNA levels were observed in 293T producer cells as well as in X-CGD PLB-985 cells transduced with vectors containing gp91s. Most significantly, we could also detect a similar increase in eGFP-DMGMT expression from the second cistron that was not codon-optimized. Similar observations have been made for vectors containing factor VIII and factor IX cDNAs, in which codon optimization of the transgene resulted in a 10-fold increase in viral titers and improved expression levels. 38, 39 Interestingly, the extent of increased transgene expression after cDNA optimization or introduction of an intron varies tremendously between different cell lines, which underlines the importance to test a vector on target cells rather than cell lines.
The use of SIN vectors with improved titers and transgene expression levels has important advantages for gene therapy. First, there is no necessity for a strong internal promoter to drive transgene expression. The use of a weak promoter or even a cell-type-specific promoter generating physiologically adequate levels of the therapeutic protein may be sufficient for a clinical benefit and might further reduce the incidence of 
Materials and methods
Cell lines
The human X-CGD PLB-985 cell line was derived from the PLB-985 myelomonocytic leukemia cell line by disrupting the gp91 phox gene by homologous recombination. 21 The non-adherent growing K562, Jurkat and PLB-985 cells and their derivatives were grown in RPMI complemented with 10% heat-inactivated fetal bovine serum, 4 mM L-glutamine and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin). HT1080 cells were cultured in Dulbecco's modified Eagle's medium with identical supplements as stated above.
Retroviral vectors and vector production
The gammaretroviral vector backbone was derived from the SERS11.SF.GFP.W vector. 20 The eGFP gene was substituted either with the wild-type gp91 phox cDNA or the optimized gp91s cDNA. For construction of bicistronic vectors, the eGFP cassette in SERS11.SF.GFP.W or in RRL.PPT.SF.GFP.pre 40 was exchanged by a cassette containing the native gp91 phox cDNA in the first cistron and a eGFP-canine O 6 -methylguanine-methyltransferase-P144K (DMGMT) fusion, analogous to that described in Choi et al. 41 in the second cistron. In vector L.SF.gp91.iGM.W the 5 0 UTR sequence from the MFGSgp91 phox vector 42 (including the U5 region, an intron and further 280 bp of 5 0 UTR) was inserted downstream of the SFFV promoter to generate L.SF.I.gp91.iGM.W. In vector L.SF.I.gp91s.iGM.W., the native gp91 phox cDNA was exchanged with that of gp91s.
For monocistronic lentiviral vectors, the native gp91 phox cDNA or the optimized gp91 phox sequence were subcloned into the pHR-SIN SEWe lentiviral vector 43 to generate L.SF.gp91.W and L.SF.gp91s.W, respectively. Cell-free viral supernatants were generated by transient co-transfection on HEK293T cells as described elsewhere. 43 Isolation and ex vivo transduction of primary hematopoietic progenitor cells
Murine bone marrow cells were harvested from the femurs and tibias of gp91 phox knockout mice at approximately 10 weeks of age. Lin À progenitors were isolated using a StemSep mouse progenitor enrichment cocktail and negative selection columns following the manufacturer's instructions (StemCell Technologies, London, UK). Lin À cells were cultured in StemSpan SFEM serum-free medium (StemCell Technologies) supplemented with 1% penicillin/streptomycin and cytokines (100 ng/ml murine stem cell factor, 100 ng/ml mFlt3L, 100 ng/ml hIL-11 and 20 ng/ml mIL-3). Cells were transduced at an MOI of 10. At 3-4 days after transduction, 2 Â 10 5 transduced lin À cells were stained with the fluorescein isothiocyanate (FITC)-conjugated murine anti-human gp91 phox monoclonal 7D5 and PElabeled anti-Sca-1 antibody (Insight Biotechnology Ltd, London, UK) and analyzed by flow cytometry.
Human CD34+ cells were purified from the apheresis product of granulocyte colony-stimulating factormobilized peripheral blood of healthy volunteers after informed consent (protocol no. EK221102004, approved by the Institutional Review Board of the University Clinic Dresden) using MACS MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's protocol. The purity of peripheral blood CD34+ progenitor cells (CD34+ PBPC) was 498%. CD34+ PBPCs were cultured in X-VIVO10 with 1% human serum albumin (HSA); 50 ng/ml FLT3 ligand, 20 ng/ml stem cell factor, 10 ng/ml thrombopoietin and 10 ng/ml IL3. Transduction of human CD34+ PBPC was performed on RetroNectin (Takara, Shiga, Otsu, Japan)-precoated 48-well plates (1 Â 10 5 CD34+ PBPC per well) 72 h after initiation of culture using different dilutions of virus vector containing media and 5 mg/ml protamine sulfate.
Cells were analyzed by flow cytometry with a FACS Calibur (BD Biosciences, San Jose, CA, USA). EGFP-DMGMT expression was analyzed 3, 5 and 9 days after transduction, whereas gp91 phox expression was measured 3 days after transduction of K562 and PLB-985 cells or 9 days after transduction of CD34+ cells. For gp91 phox detection, cells were either stained with FITC-7D5 or stained indirectly using an unlabeled 7D5 followed by Cy5-conjugated rat anti-mouse antibody (Dianova, Hamburg, Germany). CD34+ PBPC cells were permeabilized prior to 7D5 staining. Healthy human PBPCs produce native gp91 phox starting by day 7 after initiation of culture. For comparison of gp91 phox transgene expression levels in healthy PBPC, native gp91 phox expression of non-transduced cells was subtracted.
Immunomagnetic selection of gp91
phox -expressing cells and cytochrome C assay gp91 phox -expressing cells were incubated with the cytochrome b558-specific 7D5 antibody 44 and incubated for 20 min at room temperature. After washing with phosphate-buffered saline, the cells were resuspended in phosphate-buffered saline containing RAM-IgG1 FITC Ab followed by incubation at room temperature for 15 min. After several wash steps, the cells were incubated with anti-FITC MicroBeads and applied to the separation column according to manufacturer's instructions (Miltenyi Biotec GmbH). Cytochrome C assays were carried out according to Mayo and Curnutte 22 using a Spectra MAX 340 reader (Molecular Devices, Sunnyvale, CA, USA) and the SOFTmax Version 2.02 PRO software.
Determination of viral vector copy number by real-time quantitative PCR
Genomic DNA was extracted from transduced cells using the DNeasy kit (Qiagen GmbH, Hilden, Germany). Real-time quantitative PCR to determine lentiviral copy number was performed using an ABI 7000 Sequence Detection System (ABI; Applied Biosystems, Warrington, UK). The primer sequences for WPRE were as follows: forward, 
RNA extraction and real-time PCR analysis
Total RNA was obtained using the RNeasy kit (Qiagen GmbH). After DNase treatment, RNA was reverse transcribed using 200 U M-MLV reverse transcriptase (Invitrogen Corporation, Paisley, UK) following the manufacturer's instructions. Real-time PCR was performed using the probe and primers described above. The relative quantification of RNA transcripts was performed following the Livak method (ratio ¼ 2 e ÀDDC t ). 45 
Northern blot
Analysis of 3-7.5 mg total RNA by northern blot was accomplished using the NorthernMax Kit according to the instructions of the manufacturer (Ambion Incorporation, Cambridgeshire, Paisley, UK). A 32 P-labeled WPRE fragment was used for hybridization. After several washings, the membrane was exposed to an X-ray film (Kodak BioMax MS Film; Sigma-Aldrich, Steinheim, Germany) for 4 h at À80 1C. The 18S or 28S rRNA bands were used to assess for equal amounts of loaded RNA.
